U.S. Metals and Mining Stock News

Ingevity Corporation has now completed the sale of its North Charleston crude tall oil refinery assets and most of its Performance Chemicals Industrial Specialties product line to Mainstream Pine Products, LLC, as part of a portfolio reshaping plan. This move marks a clear shift toward higher-margin activated carbon and pavement technologies, aiming to simplify operations and reduce earnings volatility across the business. Next, we’ll examine how divesting the crude tall oil refinery and...

Recently, commentary on the US Oil and Gas – Exploration and Production industry highlighted more durable natural gas demand supported by LNG exports and rising power needs, emphasizing that firms like Antero Resources could see more stable cash flows as a result. Antero Resources appears particularly positioned within this backdrop because its affiliate Antero Midstream helps secure transportation and market access, while analyst earnings estimates for 2026 point to meaningful...

Interest in SI-BONE (SIBN) picked up after Jim Cramer called the stock a “great, great speculation” on his investment program, putting a spotlight on this medical device company’s sacropelvic disorder focus. See our latest analysis for SI-BONE. The recent media attention lands on a stock that already has some momentum, with a 90 day share price return of 41.27% and a 1 year total shareholder return of 45.00%. However, the 5 year total shareholder return of 27.42% and the latest 1 day share...

Recently, John Wiley & Sons announced the launch of the Nanalysis Edition of its KnowItAll spectral analysis software, a customized platform that integrates Nanalysis’s NMR database to streamline workflows for benchtop NMR users across pharmaceutical, biotechnology, materials science, and quality control fields. This tailored software release deepens Wiley’s role in specialized scientific tools, broadening its reach beyond publishing into workflow-critical digital solutions for laboratory...

Amylyx Pharmaceuticals announced in early January 2026 that it has selected AMX0318, a long-acting GLP-1 receptor antagonist discovered with Gubra A/S, as a development candidate for post-bariatric hypoglycemia and certain other rare diseases following extensive preclinical evaluation. The program’s progression toward investigational new drug–enabling studies and a potential 2027 IND filing, alongside more than US$50.00 million in potential milestones and royalties for Gubra, highlights...

American International Group (AIG) is back in focus after the company said Chairman and CEO Peter Zaffino will step down as chief executive by mid 2026, with Eric Andersen arriving as President and CEO elect. See our latest analysis for American International Group. The leadership news landed alongside a sharp single day share price decline of about 7% earlier this week, and a softer 7 day and 90 day share price return. However, the 1 year and 5 year total shareholder returns of 11.39% and...

Cogent Communications Holdings (CCOI) has attracted attention after recent share price moves, with the stock showing mixed short term and past 3 months performance that contrasts with its longer term total return record. See our latest analysis for Cogent Communications Holdings. The recent 1 month share price return of 4.10% and 7 day share price return of 3.52% sit against a 90 day share price return decline of 46.92% and a 1 year total shareholder return decline of 67.42%. This combination...

CG Oncology has announced an expedited timeline, with topline data from its Phase 3 PIVOT-006 trial of intravesical cretostimogene grenadenorepvec in intermediate-risk non-muscle invasive bladder cancer now expected in the first half of 2026, alongside ongoing Phase 2 and Phase 3 studies and an Expanded Access Program in North America. This is the first randomized Phase 3 trial in this intermediate-risk bladder cancer population under AUA/SUO guideline definitions, positioning cretostimogene...

In recent months, analysts at major banks including Citigroup and UBS have reiterated positive ratings on Olema Pharmaceuticals, citing confidence in its clinical-stage pipeline and strengthened balance sheet following a roughly US$218.5 million public offering in November 2025. An interesting angle for investors is Olema’s inclusion on Citigroup’s 90-day catalyst watchlist, highlighting expectations around upcoming clinical and corporate milestones. Next, we’ll examine how Olema’s addition...

When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

AZZ (AZZ) has put up a busy run of quarters ahead of its Q3 2026 report, with Q3 fiscal revenue at US$425.7 million and basic EPS of US$1.37, sitting alongside trailing 12 month revenue of about US$1.6 billion and EPS of US$10.73. Over recent periods the company has seen quarterly revenue move from US$403.7 million in Q3 2025 to US$351.9 million in Q4 2025, then into the US$422.0 million to US$425.7 million range in Q1 to Q3 2026, while basic EPS has ranged from US$0.68 in Q4 2025 to US$5.71...

If you are wondering whether Ventas at around US$75 is offering good value today, you are not alone. This article is designed to help you size that up clearly. The stock has pulled back recently, with a 3% decline over the last 7 days and a 6.2% decline over the last 30 days. The 1 year return sits at 32.5%, the 3 year at 66.9%, and the 5 year at 83.8%. Recent attention on Ventas has focused on its position in the healthcare real estate sector and how investors view that exposure as interest...

If you are wondering whether UDR is priced attractively today, this article walks through what the current numbers suggest about the stock's value. UDR recently closed at US$37.32, with returns of 1.7% over the last week, 6.9% over the last month, 1.7% year to date, and a 5.4% decline over the past year. This gives a mixed picture of recent performance. Recent coverage around UDR has focused on how investors are reassessing listed residential real estate, with pricing and capital allocation...

If you are wondering whether Block's current share price lines up with its underlying worth, you are not alone. This article is built to help you weigh that question clearly. Block's stock last closed at US$70.16, with returns of 7.8% over the past week, 14.0% over the past month, 7.7% year to date, and a 19.1% decline over the past year, as well as 2.3% and 69.9% declines over the last 3 and 5 years respectively. Recent headlines for Block have focused on its role in digital payments and...

Arbe Robotics recently announced at CES 2026 that it is combining its automotive-grade ultra‑HD radar with NVIDIA’s accelerated computing to create an AI-based perception platform designed for hands-off, eyes-off driving, featuring over 20,000 detections per frame and more than 300 meters of range in varied weather conditions. A distinctive aspect of this development is how the dense radar point cloud, processed on NVIDIA’s in-vehicle computing, is being used to build AI-based occupancy...

Recent reaffirmations of positive ratings on Parker-Hannifin (PH) have put fresh attention on the industrial supplier, as analysts react to its steady financial results, dividends, and push into higher margin aerospace and motion control markets. See our latest analysis for Parker-Hannifin. The reaffirmed positive sentiment from analysts has arrived alongside solid recent momentum, with a 90 day share price return of 26.49% and a 1 year total shareholder return of 42.68%, suggesting interest...

Jefferies coverage initiation puts Goosehead Insurance in focus Jefferies has initiated coverage on Goosehead Insurance (GSHD), highlighting the company’s low-risk expansion through independent agency partnerships, its position in the property and casualty market, and a broker model focused on retention and commissions. See our latest analysis for Goosehead Insurance. Goosehead Insurance’s share price has moved to US$74.80, with a 90-day share price return of 9.09%. The 1-year total...

If you are wondering whether XPeng's current share price still offers value, you are not alone. This article is built to help you weigh what the market might be pricing in. XPeng shares last closed at US$20.52, with returns of 1.2% over 7 days, 3.6% over 30 days, 0.4% year to date, 69.0% over 1 year and 103.0% over 3 years, while the 5 year return stands at a 59.2% decline. Recent coverage of XPeng has focused on its position in the electric vehicle space and the market's changing...

Q3 revenue surprise puts XPEL (XPEL) back in focus Recent attention on XPEL (XPEL) stems from its Q3 results, where revenue growth surpassed expectations while earnings per share came in below forecasts. This has prompted investors to reassess the trade off between sales momentum and profitability. See our latest analysis for XPEL. At a share price of $54.63, XPEL has climbed sharply in recent months, with a 90 day share price return of 61.18% and a 1 year total shareholder return of 39.35%...

On 9 January 2026, Schrödinger, Inc. announced a collaboration with Eli Lilly’s TuneLab platform, integrating TuneLab’s AI-driven drug discovery workflows into Schrödinger’s LiveDesign enterprise informatics environment via a privacy-preserving federated learning framework. This arrangement highlights Schrödinger’s role within a wider ecosystem of leading AI and machine-learning providers supporting Lilly’s efforts to accelerate drug discovery while keeping partner data separate and...

First Interstate BancSystem (FIBK) is drawing fresh attention as several analysts turn more optimistic on the regional bank, citing improving sector conditions and loan growth prospects in connection with its upcoming quarterly earnings report. See our latest analysis for First Interstate BancSystem. The recent analyst upgrades and upcoming earnings call sit against a stronger price backdrop, with a 23.58% 90 day share price return and a 25.47% 1 year total shareholder return suggesting...

Webull (BULL) is drawing fresh attention after its Australian subsidiary launched Vega AI, an AI-powered investment assistant that offers real-time market analysis, 24/7 decision support, and streamlined financial report summaries for local users. See our latest analysis for Webull. Vega AI arrives at a time when Webull’s short term momentum has been mixed, with a 7-day share price return of 8.49% and a 30-day share price return of a 17.76% decline, while the 1-year total shareholder return...

Tecnoglass (TGLS) shares fell 5.5% after the company issued full-year EBITDA guidance that investors viewed as weak. At the same time, competitor Apogee Enterprises cut its outlook, reinforcing concerns about demand and cost pressures. See our latest analysis for Tecnoglass. At a share price of $51.23, Tecnoglass has a 1-day share price return of 6.86%, but a 90-day share price return decline of 17.46% and a 1-year total shareholder return loss of 30.55%, suggesting momentum has been fading...